Ignite Creation Date:
2025-12-24 @ 11:53 PM
Ignite Modification Date:
2025-12-25 @ 9:48 PM
Study NCT ID:
NCT02198651
Status:
COMPLETED
Last Update Posted:
2019-06-25
First Post:
2014-07-22
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects
Sponsor:
AbbVie
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-01-05
Start Date Type:
ACTUAL
Primary Completion Date:
2018-05-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-08-08
Completion Date Type:
ACTUAL
First Submit Date:
2014-07-22
First Submit QC Date:
None
Study First Post Date:
2014-07-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-04-29
Results First Submit QC Date:
None
Results First Post Date:
2019-06-25
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-06-06
Last Update Post Date:
2019-06-25
Last Update Post Date Type:
ACTUAL